GlassScriptPhysician profile
Vincent Kolanko
NPI 1225009525
$1,262.18
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $951 · 2020: $275 · 2021: $36.37.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $203.93 | 2019 | |
| Novo Nordisk INC | $181.17 | 2019-2021 | |
| Tris Pharma INC | $94.73 | 2019-2020 | |
| Astellas Pharma US INC | $92.58 | 2019-2020 | |
| Allergan, INC. | $83.06 | 2019-2020 | |
| Lilly USA, LLC | $80.57 | 2019 | |
| Neos Therapeutics, LP | $69.78 | 2019-2020 | |
| Glaxosmithkline, LLC. | $56.09 | 2019 | |
| Amgen INC. | $54.78 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $48.99 | 2019 | |
| Pfizer INC. | $40.57 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.17 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $29.03 | 2020 | |
| Abbvie INC. | $27.41 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $26.85 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $25.64 | 2019 | |
| Ethicon US, LLC | $25.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $23.03 | 2019-2020 | |
| Alkermes, INC. | $19.03 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.72 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $12.35 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.79 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.30 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Kolanko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.